Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 5/10

vs
industry
vs
history
Cash-to-Debt 3.41
NAS:SCYX's Cash-to-Debt is ranked higher than
57% of the 799 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.05 vs. NAS:SCYX: 3.41 )
Ranked among companies with meaningful Cash-to-Debt only.
NAS:SCYX' s Cash-to-Debt Range Over the Past 10 Years
Min: 0.04  Med: No Debt Max: No Debt
Current: 3.41
Equity-to-Asset 0.61
NAS:SCYX's Equity-to-Asset is ranked lower than
58% of the 731 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 0.64 vs. NAS:SCYX: 0.61 )
Ranked among companies with meaningful Equity-to-Asset only.
NAS:SCYX' s Equity-to-Asset Range Over the Past 10 Years
Min: -8.73  Med: 0.82 Max: 0.89
Current: 0.61
-8.73
0.89
Debt-to-Equity 0.46
NAS:SCYX's Debt-to-Equity is ranked lower than
61% of the 568 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 0.30 vs. NAS:SCYX: 0.46 )
Ranked among companies with meaningful Debt-to-Equity only.
NAS:SCYX' s Debt-to-Equity Range Over the Past 10 Years
Min: -0.4  Med: 0.41 Max: 0.46
Current: 0.46
-0.4
0.46
Piotroski F-Score: 2
Altman Z-Score: -3.89
Beneish M-Score: -4.10
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 2/10

vs
industry
vs
history
Operating Margin % -9803.91
NAS:SCYX's Operating Margin % is ranked lower than
98% of the 758 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 7.95 vs. NAS:SCYX: -9803.91 )
Ranked among companies with meaningful Operating Margin % only.
NAS:SCYX' s Operating Margin % Range Over the Past 10 Years
Min: -10823.74  Med: -46.23 Max: 11030.74
Current: -9803.91
-10823.74
11030.74
Net Margin % -9275.39
NAS:SCYX's Net Margin % is ranked lower than
98% of the 759 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 6.06 vs. NAS:SCYX: -9275.39 )
Ranked among companies with meaningful Net Margin % only.
NAS:SCYX' s Net Margin % Range Over the Past 10 Years
Min: -12693.77  Med: -337.1 Max: -68.17
Current: -9275.39
-12693.77
-68.17
ROE % -67.05
NAS:SCYX's ROE % is ranked lower than
92% of the 780 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 6.91 vs. NAS:SCYX: -67.05 )
Ranked among companies with meaningful ROE % only.
NAS:SCYX' s ROE % Range Over the Past 10 Years
Min: -86.56  Med: -82.35 Max: -67.05
Current: -67.05
-86.56
-67.05
ROA % -41.98
NAS:SCYX's ROA % is ranked lower than
90% of the 805 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.71 vs. NAS:SCYX: -41.98 )
Ranked among companies with meaningful ROA % only.
NAS:SCYX' s ROA % Range Over the Past 10 Years
Min: -248.61  Med: -73.36 Max: -16.27
Current: -41.98
-248.61
-16.27
3-Year Revenue Growth Rate -89.00
NAS:SCYX's 3-Year Revenue Growth Rate is ranked lower than
99.99% of the 634 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 5.10 vs. NAS:SCYX: -89.00 )
Ranked among companies with meaningful 3-Year Revenue Growth Rate only.
NAS:SCYX' s 3-Year Revenue Growth Rate Range Over the Past 10 Years
Min: 0  Med: -44.5 Max: -89
Current: -89
3-Year EBITDA Growth Rate -47.70
NAS:SCYX's 3-Year EBITDA Growth Rate is ranked lower than
99.99% of the 601 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 8.90 vs. NAS:SCYX: -47.70 )
Ranked among companies with meaningful 3-Year EBITDA Growth Rate only.
NAS:SCYX' s 3-Year EBITDA Growth Rate Range Over the Past 10 Years
Min: 0  Med: -23.85 Max: -47.7
Current: -47.7
3-Year EPS without NRI Growth Rate -51.90
NAS:SCYX's 3-Year EPS without NRI Growth Rate is ranked lower than
99.99% of the 576 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 7.60 vs. NAS:SCYX: -51.90 )
Ranked among companies with meaningful 3-Year EPS without NRI Growth Rate only.
NAS:SCYX' s 3-Year EPS without NRI Growth Rate Range Over the Past 10 Years
Min: 0  Med: -25.95 Max: -51.9
Current: -51.9
GuruFocus has detected 3 Warning Signs with SCYNEXIS Inc $NAS:SCYX.
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.
» NAS:SCYX's 30-Y Financials

Financials (Next Earnings Date: 2017-11-07 Est.)


Revenue & Net Income
Cash & Debt
Operating Cash Flow & Free Cash Flow
Operating Cash Flow & Net Income

» Details

Insider Trades

Latest Guru Trades with NAS:SCYX

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Drug Manufacturers » Drug Manufacturers - Specialty & Generic    NAICS: 325412    SIC: 2834
Compare:OTCPK:MCOA, NAS:ATXI, NAS:EVOK, NAS:FCSC, NAS:JNP, NAS:PSDV, NAS:GALT, OTCPK:SENZ, OTCPK:COSM, NAS:BPTH, XCNQ:IAN, NAS:OREX, OTCPK:STNY, NAS:IMMY, NAS:PTX, OTCPK:ELTP, NAS:LPCN, NAS:SNOA, NAS:APRI, OTCPK:CXBS » details
Traded in other countries:135.Germany,
Headquarter Location:USA
SCYNEXIS Inc is a pharmaceutical company engaged in the discovery, development, and commercialization of novel anti-infectives to address unmet therapeutic needs.

SCYNEXIS Inc was incorporated in Delaware in November 4, 1999 as ScyRex, Inc. In June 2002, the Company changed its name to SCYNEXIS Inc. It is a pharmaceutical company engaged in the discovery, development, and commercialization of novel anti-infectives to address unmet therapeutic needs. The Company is developing its product candidate SCY-078, as a novel oral and intravenous drug for the treatment of serious and life-threatening invasive fungal infections in humans. In addition, it has a clinical and preclinical programs based on the use of cyclophilin inhibitors to treat viral diseases. It also provides contract research and development services in the field of animal health. The Company's competitors include pharmaceutical and biotechnology companies, and specialty pharmaceutical and generic drug companies.

Ratios

vs
industry
vs
history
PB Ratio 1.98
SCYX's PB Ratio is ranked higher than
81% of the 751 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.80 vs. SCYX: 1.98 )
Ranked among companies with meaningful PB Ratio only.
SCYX' s PB Ratio Range Over the Past 10 Years
Min: 1.08  Med: 1.94 Max: 3.5
Current: 1.98
1.08
3.5
PS Ratio 215.45
SCYX's PS Ratio is ranked lower than
96% of the 736 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.97 vs. SCYX: 215.45 )
Ranked among companies with meaningful PS Ratio only.
SCYX' s PS Ratio Range Over the Past 10 Years
Min: 0.42  Med: 121.81 Max: 303.91
Current: 215.45
0.42
303.91
EV-to-EBIT -1.29
SCYX's EV-to-EBIT is ranked lower than
99.99% of the 559 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 20.11 vs. SCYX: -1.29 )
Ranked among companies with meaningful EV-to-EBIT only.
SCYX' s EV-to-EBIT Range Over the Past 10 Years
Min: -13.4  Med: -1 Max: 3
Current: -1.29
-13.4
3
EV-to-EBITDA -1.29
SCYX's EV-to-EBITDA is ranked lower than
99.99% of the 587 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 17.50 vs. SCYX: -1.29 )
Ranked among companies with meaningful EV-to-EBITDA only.
SCYX' s EV-to-EBITDA Range Over the Past 10 Years
Min: -16.9  Med: -1 Max: 3
Current: -1.29
-16.9
3
EV-to-Revenue 111.20
SCYX's EV-to-Revenue is ranked lower than
88% of the 755 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.22 vs. SCYX: 111.20 )
Ranked among companies with meaningful EV-to-Revenue only.
SCYX' s EV-to-Revenue Range Over the Past 10 Years
Min: -81.5  Med: 39.2 Max: 304.7
Current: 111.2
-81.5
304.7
Current Ratio 10.88
SCYX's Current Ratio is ranked higher than
96% of the 782 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.40 vs. SCYX: 10.88 )
Ranked among companies with meaningful Current Ratio only.
SCYX' s Current Ratio Range Over the Past 10 Years
Min: 0.11  Med: 9.77 Max: 16.55
Current: 10.88
0.11
16.55
Quick Ratio 10.88
SCYX's Quick Ratio is ranked higher than
96% of the 782 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.82 vs. SCYX: 10.88 )
Ranked among companies with meaningful Quick Ratio only.
SCYX' s Quick Ratio Range Over the Past 10 Years
Min: 0.11  Med: 9.77 Max: 16.55
Current: 10.88
0.11
16.55
Days Sales Outstanding 357.87
SCYX's Days Sales Outstanding is ranked lower than
98% of the 651 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 74.70 vs. SCYX: 357.87 )
Ranked among companies with meaningful Days Sales Outstanding only.
SCYX' s Days Sales Outstanding Range Over the Past 10 Years
Min: 15.57  Med: 65.68 Max: 1320.82
Current: 357.87
15.57
1320.82

Buy Back

vs
industry
vs
history
3-Year Average Share Buyback Ratio -149.70
SCYX's 3-Year Average Share Buyback Ratio is ranked lower than
99.99% of the 473 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: -4.10 vs. SCYX: -149.70 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
SCYX' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -149.7  Med: -74.85 Max: 0
Current: -149.7
-149.7
0

Valuation & Return

vs
industry
vs
history
Price-to-Net-Cash 2.15
SCYX's Price-to-Net-Cash is ranked higher than
97% of the 239 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 11.21 vs. SCYX: 2.15 )
Ranked among companies with meaningful Price-to-Net-Cash only.
SCYX' s Price-to-Net-Cash Range Over the Past 10 Years
Min: 1.25  Med: 2.23 Max: 3.69
Current: 2.15
1.25
3.69
Price-to-Net-Current-Asset-Value 2.04
SCYX's Price-to-Net-Current-Asset-Value is ranked higher than
95% of the 512 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 7.25 vs. SCYX: 2.04 )
Ranked among companies with meaningful Price-to-Net-Current-Asset-Value only.
SCYX' s Price-to-Net-Current-Asset-Value Range Over the Past 10 Years
Min: 1.18  Med: 2.1 Max: 3.46
Current: 2.04
1.18
3.46
Price-to-Tangible-Book 1.98
SCYX's Price-to-Tangible-Book is ranked higher than
83% of the 690 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.51 vs. SCYX: 1.98 )
Ranked among companies with meaningful Price-to-Tangible-Book only.
SCYX' s Price-to-Tangible-Book Range Over the Past 10 Years
Min: 1.16  Med: 2.06 Max: 2.73
Current: 1.98
1.16
2.73
Price-to-Median-PS-Value 1.77
SCYX's Price-to-Median-PS-Value is ranked lower than
63% of the 712 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.09 vs. SCYX: 1.77 )
Ranked among companies with meaningful Price-to-Median-PS-Value only.
SCYX' s Price-to-Median-PS-Value Range Over the Past 10 Years
Min: 0.02  Med: 1.21 Max: 2.28
Current: 1.77
0.02
2.28
Earnings Yield (Greenblatt) % -78.72
SCYX's Earnings Yield (Greenblatt) % is ranked lower than
100% of the 805 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.10 vs. SCYX: -78.72 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) % only.
SCYX' s Earnings Yield (Greenblatt) % Range Over the Past 10 Years
Min: -7612.2  Med: -36.05 Max: 8156.7
Current: -78.72
-7612.2
8156.7

More Statistics

Revenue (TTM) (Mil) $0.26
EPS (TTM) $ -0.94
Beta0.23
Short Percentage of Float8.20%
52-Week Range $1.52 - 5.51
Shares Outstanding (Mil)26.72

Analyst Estimate

Dec17 Dec18 Dec19 Dec20
Revenue (Mil $) 0 0 0 28
EPS ($) -1.19 -1.62 -1.30 -0.66
EPS without NRI ($) -1.19 -1.62 -1.30 -0.66
EPS Growth Rate
(Future 3Y To 5Y Estimate)
N/A
Dividends per Share ($)
» More Articles for NAS:SCYX

Headlines

Articles On GuruFocus.com
SCYNEXIS to Present at Upcoming Investor Conferences Aug 31 2017 
“THINK FUNGUS” - SCYNEXIS Recognizes Fungal Disease Awareness Week Sponsored by the Center Aug 15 2017 
SCYNEXIS Presents New Data Supporting Oral SCY-078 for the Clinical Treatment of Vulvovaginal Candid Aug 14 2017 
SCYNEXIS Reports Second Quarter 2017 Financial Results and Provides Company Update Aug 08 2017 
SCYNEXIS to Present at the Canaccord Genuity Growth Conference Aug 07 2017 
SCYNEXIS Announces Initiation of Dosing in Phase 2 Study Evaluating Oral SCY-078 in Vulvovaginal Can Aug 03 2017 
Antimicrobial Working Group Members to Participate in 2017 BIO International Convention Panel Jun 19 2017 
New Study Further Demonstrates In Vitro Activity of SCYNEXIS’ Lead Anti-Infective Candidate, SC Jun 15 2017 
SCYNEXIS, Inc. to Participate in the 2017 BIO International Convention Jun 13 2017 
Eight Presentations at ASM Microbe 2017 Further Highlight the Strong Antifungal Effect and Promising Jun 05 2017 

More From Other Websites
What Does SCYNEXIS Inc’s (SCYX) Share Price Indicate? Sep 13 2017
ETFs with exposure to SCYNEXIS, Inc. : September 1, 2017 Aug 31 2017
SCYNEXIS to Present at Upcoming Investor Conferences Aug 31 2017
SCYNEXIS, Inc. :SCYX-US: Earnings Analysis: Q2, 2017 By the Numbers : August 24, 2017 Aug 24 2017
“THINK FUNGUS” - SCYNEXIS Recognizes Fungal Disease Awareness Week Sponsored by the Centers for... Aug 15 2017
SCYNEXIS Presents New Data Supporting Oral SCY-078 for the Clinical Treatment of Vulvovaginal... Aug 14 2017
SCYNEXIS Reports Second Quarter 2017 Financial Results and Provides Company Update Aug 08 2017
SCYNEXIS to Present at the Canaccord Genuity Growth Conference Aug 07 2017
SCYNEXIS Announces Initiation of Dosing in Phase 2 Study Evaluating Oral SCY-078 in Vulvovaginal... Aug 03 2017
Antimicrobial Working Group Members to Participate in 2017 BIO International Convention Panel Jun 19 2017
ETFs with exposure to SCYNEXIS, Inc. : June 14, 2017 Jun 14 2017
SCYNEXIS, Inc. :SCYX-US: Earnings Analysis: Q1, 2017 By the Numbers : May 12, 2017 May 12 2017
Scynexis reports 1Q loss May 08 2017
SHAREHOLDER ANNOUNCEMENT: Levi & Korsinsky, LLP Reminds Shareholders of SCYNEXIS, Inc. of a Class... May 08 2017

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)

GF Chat

{{numOfNotice}}